Exhibit 10.1
Paradigm Genetics, Inc. has omitted from this Exhibit 10.1 portions of the
Agreement for which Paradigm Genetics, Inc. has requested confidential treatment
from the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934. The portions of the Agreement for which
confidential treatment has been requested have been filed separately with the
Securities and Exchange Commission and are marked by asterisks.
AMENDMENT NUMBER 2
To
Monsanto/Paradigm Genetics Collaboration Agreement
THIS IS AN AMENDMENT to the Monsanto/Paradigm Genetics Collaboration
Agreement dated as of November 17, 1999 (the "Agreement"), effective as of
________, by and between Paradigm Genetics Inc., a corporation organized under
the laws of Delaware, having its principal place of business at 000 Xxxxxxxxx
Xxxxx, Xxxxxxxx 0X, X.X. Xxx 00000, Research Triangle Park, North Carolina 2709
("Paradigm") and Monsanto Company ("Monsanto"), a Delaware corporation, having a
principal place of business at 000 Xxxxx Xxxxxxxxx Xxxxxxxxx, Xx. Xxxxx,
Xxxxxxxx 00000.
WHEREAS, the parties have agreed to modify the Agreement as set forth
herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth, the parties agree as follows:
1. DEFINITIONS
1.1 Terms defined in the Agreement are used herein as so defined.
1.2 In addition, for purposes of the Agreement, as amended hereby, the following
words and phrases shall have the following meanings:
1.34 Homolog
"Homolog" shall mean DNA which encodes a protein whereby the protein
is more than 50% similar to a protein encoded by Monsanto DNA
Information, as determined using a global alignment across the
entire length of the two proteins with the GCG GAP program
configured with default parameters (matrix = Blossum62, Gap Creation
Penalty = 8, Gap Extension Penalty = 2) and whereby the Homolog and
the Monsanto DNA Information confers substantially the identical
trait using standard transgene technologies, including but not
limited to over-expression, antisense or knockout technologies. As
an example of "substantially the identical trait," cold tolerance of
2 degrees centigrade should be considered to be substantially the
identical trait as cold tolerance of 10 degrees centigrade, but not
considered the substantially identical trait as freeze tolerance
2
(below 0 degrees centigrade) or heat tolerance (above 28 degrees
centigrade).
1.35 Monsanto Designated Crop
"Monsanto Designated Crop" shall mean all cereal crops (including
corn, wheat, rice and barley), all oil crops (including soybean,
oilseed rape, canola and sunflower), sorghum, potato, cotton,
alfalfa, sugarcane and turf.
1.36 Monsanto Enabling Assets
"Monsanto Enabling Assets" shall mean the technologies that are
subject to the claims of the patents and patent applications and any
and all patents maturing from applications that are divisionals,
continuations or continuations-in-part of these applications and any
and all reissues or extensions of any of the foregoing that are
listed in Appendix L. Monsanto Enabling Assets are a subset of
Monsanto Enabling Technology.
1.37 Paradigm Fine Chemical Field
"Paradigm Fine Chemical Field" shall mean the production in any
plant of fragrances, flavors (including, without limitation, mint),
Drugs and Dietary Supplements.
1.39 Paradigm Enabled Products
"Paradigm Enabled Products" shall mean products whose development,
manufacture, use or sale, in the absence of the license granted by
Article 2.12, would infringe at least one (1) claim of an unexpired
U.S. or foreign patent owned or controlled by Monsanto covering the
Monsanto Enabling Assets.
1.40 Paradigm Technology
"Paradigm Technology" shall mean any materials, know-how,
information, discoveries or inventions that are discovered or
developed by Paradigm or in-licensed by Paradigm.
3
1.41 Transcription Factor
"Transcription Factor" shall mean a protein that associates with or
near the promoter region of a gene and thereby regulates
transcription of such gene.
1.42 Submitted for Regulatory Approval
"Submitted for Regulatory Approval" shall mean a submission to the
appropriate regulatory agency in any one of the United States, the
European Union and Japan of a properly completed application that,
if approved by the agency, would permit commercialization of the
product without filing any additional applications. Whether or not
the agency approves of the product or requires additional
information is not relevant in determining the products' status as
Submitted for Regulatory Approval.
1.43 Permitted Assignee
"Permitted Assignee" shall mean an entity that did not derive
significant revenues from the sale of seeds or crop protection
products in its most recent fiscal year preceding the date of
determination of whether such entity is a Permitted Assignee.
1.44 Nominations
"Nominations" shall mean either 1) Arabidopsis sequence-verified
constructs in the appropriate binary vectors; or 2) as Arabidopsis
sequence information and suggested 5' and 3' primers for PCR-based
cloning at Paradigm.
1.45 Reservations
"Reservations" shall mean Arabidopsis DNA sequence information which
comprises either the full sequence of a gene (including the start
and stop codon) or sufficient information to uniquely identify a
single gene.
1.46 Drugs and Dietary Supplements
"Drugs" and "Dietary Supplements" shall have the meaning as set out
in 21
4
U.S.C. xx.xx. 321(g) and (ff) as of January 23, 2000.
1.3 Amended Definitions
The Agreement is amended by replacing Articles 1.11 and 1.18 with the
following Article.
1.11. Improvements
"Improvements" shall mean any improvements to Monsanto Enabling
Technology and Monsanto Enabling Assets. Improvements may or may not
result in patentable subject matter.
1.18 Net Product Revenues
"Net Product Revenues" shall mean the gross invoiced sales of
Licensed Products or Paradigm Enabled Products received by Paradigm,
its Affiliates or, in the case of Paradigm Enabled Products, its
licensee during the applicable period in arm's length transactions
after deduction of the following items, provided and to the extent
such items are actually incurred and do not exceed reasonable and
customary amounts in each market in which such sales occurred: (1)
trade and quantity discounts and rebates; (ii) credits or allowances
made for rejection or return of previously sold Licensed Products or
Paradigm Enabled Products; (iii) any tax or government charge levied
on the sale, such as value added tax (but not including income tax);
and (iv) any charges for freight or insurance. In the event that the
Licensed Product or Paradigm Enabled Product is not sold or is used
internally by Paradigm, an Affiliate of Paradigm, or, in the case of
Paradigm Enabled Products, its licensee, or is sold or otherwise
transferred to a third party for a price lower than if it had been
sold to a third party in an arm's length transaction ("fair market
value"), then Net Product Revenues shall be the fair market value of
the Licensed Product or Paradigm Enabled Product.
2. CONVEYANCE OF RIGHTS
5
2.1. Expanded Rights for Monsanto Enabling Assets
The Agreement is amended by adding the following Articles:
2.12 License to Paradigm: Additional Rights to Monsanto Enabling Assets in
Paradigm Fine Chemical Field.
In addition to the rights granted in Article 2.9, Monsanto grants to
Paradigm under Monsanto's interest in Monsanto Enabling Assets, (a) a
worldwide non-exclusive license to use Monsanto Enabling Assets in the
Paradigm Fine Chemical Field, and (b) a worldwide non-exclusive license to
develop, make, have made, import, use, sell, have sold and offer to sell:
i) plants that have been developed with the use of Monsanto Enabling
Assets that contain fragrances, flavors (including, without limitation,
mint), Drugs and Dietary Supplements and; ii) fragrances, flavors
(including, without limitation, mint), Drugs and Dietary Supplements
produced from such plants, provided that such license shall not include
the right to commercialize Drugs prior to September 1, 2002. Paradigm
shall not have the right to grant sublicenses under the license granted by
this Article 2.12 to third parties to use Monsanto Enabling Assets
(including the right to transform plants with vectors supplied by
Paradigm), but shall have the limited right to grant sublicenses under the
license granted by this Article 2.12 to third parties (i) to propagate,
grow, harvest, use, sell, have sold and offer to sell plants that both
contain Paradigm Technology and have been developed or transformed by
Paradigm with the use of Monsanto Enabling Assets including progeny of
such plants, and (ii) to make, have made, import, use, sell, have sold and
offer to sell fragrances, flavors (including, without limitation, mint),
Drugs and Dietary Supplements produced from such plants that contain
Paradigm Technology and progeny of such plants; further provided that if
the Paradigm Technology has been in-licensed by Paradigm, then any such
sublicense under this Article 2.12 shall not be exclusive to the provider
of the in-licensed Paradigm Technology. The grant under this Article 2.12
is limited to only those items of Monsanto Enabling Technology that are
defined as Monsanto Enabling Assets. Paradigm shall be responsible for
maintaining sufficient records on the use of Monsanto Enabling Assets so
that plants can be identified. Paradigm agrees to grant and hereby grants
a royalty-free, nonexclusive license to Monsanto to any Improvements
created
6
by Paradigm.
2.2 Amended Grants
The Agreement is amended by replacing Article 2.11 with the following
Article.
2.11. License to Paradigm: restriction on license
Nothing in this Agreement shall be construed as granting a license
under any Monsanto patents other than Licensed Patent Rights,
Monsanto Enabling Technology and Monsanto Enabling Assets. No
license is granted to any Licensed Product which infringes a
Monsanto patent that is not included in Licensed Patent Rights,
Monsanto Enabling Technology and Monsanto Enabling Assets.
3. FUNDED PROJECT AND REPLACEMENT OF APPENDICES
3.1 Revised Quantities of Monsanto DNA Information
The Agreement is amended by replacing Articles 3.2.1 and 3.2.3 with the
following Article:
3.2.1 Monsanto DNA supplied
In the case of Monsanto DNA Information relating to a species other
than Arabidopsis, such Monsanto DNA Information shall be in the form
of a DNA clone containing a full-length open reading frame or in a
form that does not require any cloning on behalf of Paradigm. For
each such non-Arabidopsis DNA, Paradigm will provide an appropriate
ortholog from Arabidopsis, if one is available. Monsanto agrees to
provide to Paradigm primers from Arabidopsis that Paradigm can use
to obtain such orthologs. Under the Project Plan, Monsanto shall be
limited to providing no more than [____]* non-Arabidopsis DNA of
which no more than [____________]* will be from rice, no more than
[____________]* will be from Aspergillus and no more than
[____________]* will be from filamentous fungal phytopathogens.
These amounts will be proportionally expanded if Monsanto exercises
the options under Articles 4.1.5.2 or 4.1.5.3. Monsanto will use
diligent efforts to assure that all Monsanto DNA Information is
accurate.
3.2.3 Counting for failed experiments
In the event that Paradigm attempts diligently to insert the DNA
from any Monsanto DNA Information into Arabidopsis as set forth in
the Project Plan but is unable to do so, the remediation activities
specified in the Project Plan will
7
be undertaken and the achievement of the Production Target Levels
will be calculated as specifically set forth in the Project Plan.
3.2 Replacement Appendices B, C, F, and H
Appendices B, C, F, and H are deleted from the Agreement and replaced with
Appendices B, C, F, and H attached hereto. Appendix L and M are added to
the Agreement.
3.2.6 Nominations
(a) Monsanto shall submit Nominations as set forth in the Project Plan.
Paradigm shall provide Monsanto quarterly and within 5 business days of
request with a list of Nominations for which Paradigm has not yet
commenced the first attempt to clone a sense construct in accordance with
the Project Plan. Monsanto shall have the right to withdraw any Nomination
on such list and substitute a different Nomination from the list of
Reservations by written notice given within five (5) business days of
receipt of the list. Paradigm agrees to make further substitutions upon
request to the extent that cloning for the requested substitute Nomination
has not yet been attempted. The withdrawn Nomination shall revert to the
status of a Reservation, subject to substitution pursuant to Section 3.2.4
at Monsanto's option.
(b) The parties shall, on a quarterly basis, review Paradigm's backlog of
Nominations not yet successfully cloned and, if appropriate, shall reduce
the rate at which Nominations are provided by Monsanto pursuant to the
Project Plan to the level necessary to sustain target production levels
and necessary work buffers at Paradigm.
4. PAYMENTS
4.1. The Agreement is amended by adding the following Articles.
4.6 Royalties - Paradigm Enabled Products
Paradigm shall pay a royalty based on the aggregate Net Product
Revenues of all Paradigm Enabled Products sold by Paradigm or a
licensee of Paradigm subject to the following conditions:
4.6.1 Royalty Rate
The royalty rate shall be based on the particular Monsanto Enabling
Assets utilized in the development of the Paradigm Enabled Product
as follows:
8
Monsanto Enabling Assets Royalty Rate
------------------------ ------------
35S Promoter 1.0%
NPT2 Antibiotic Resistance Gene 0.5%
Agrobacterium Transformation 1.0%
4.6.2 Cumulative Royalties
Royalties shall be paid on a product-by-product basis. In the event
that only one Monsanto Enabling Asset is present or used in the
product, for instance, 35S Promoter, then only one royalty shall be
due and payable at the applicable rate regardless of the number of
patents covering the particular Monsanto Enabling Asset practiced by
Paradigm and sublicensees in connection with the production and
commercialization of a particular Paradigm Enabled Product. In the
event that two or more Monsanto Enabling Assets are present or used
in the product, for instance, 35S Promoter and Agrobacterium
Transformation, then the sum of the royalties shall be due (in the
example, a 2% royalty would be due).
4.6.2 No Non-Monetary Consideration for Sales:
Paradigm shall not accept or solicit any non-monetary consideration
in the sale by Paradigm or sublicensee of Paradigm of any Paradigm
Enabled Product, other than as would be reflected in the calculation
of Net Product Revenues, as the case may be.
5. CERTAIN USES OF MONSANTO DNA INFORMATION
5.1. Effect of Uses of Monsanto DNA Information
The Agreement is amended by adding the following Section 7.10.
7.10 Effect of Uses of Monsanto DNA Information
Without limiting the generality of the other provisions of this
Article 7, if Paradigm utilizes Monsanto DNA Information or if
Paradigm or Monsanto utilizes Project Technology developed in the
course of carrying out the Project Plan for a third party or for
itself and such use materially contributes to the
9
conception or reduction to practice of any of the following:
(i) any Homolog of any gene represented by the Monsanto DNA
Information;
(ii) any gene whose transcription or translation is controlled
by Monsanto DNA Information or its Homolog;
(iii) any Arabidopsis Transcription Factor that regulates
transcription of Monsanto DNA Information or its Homolog; or
(iv) any protein which interacts with Monsanto DNA Information
or is in an interaction pathway with Monsanto DNA Information
and, in either case, that can be used to create the same trait
as such Monsanto DNA Information,
then such invention or discovery shall be included in Project
Technology and, if patented, Licensed Patents, with the exception
that the inventions or discoveries from such use by Monsanto shall
not be licensed to Paradigm and with the further exception that the
licenses granted to Monsanto shall be limited to the field of
Monsanto Designated Crops. The foregoing shall not apply to any
other use of Monsanto DNA Information permitted by this Agreement,
including without limitation use of Monsanto DNA Information and
Project Technology to determine or confirm the function of DNA
discovered without the use of Monsanto DNA Information described
above. The foregoing shall not apply to any use of information
obtained independently from the Project Plan by Paradigm, even if
such information is the same as Monsanto DNA Information or Project
Technology. In addition, Paradigm shall have the right to use
Monsanto DNA Information in any way for the purpose of discovering
genes or proteins that are targets for herbicides with the proviso
that any gene or protein discovered shall be licensed to Monsanto as
Licensed Patents for all uses other than as targets for herbicide
discovery.
10
6. FUNDED PROJECT
6.1. Amendments Relating To Supply Of Monsanto DNA Information
The Agreement is amended by adding the following Articles 3.2.4, 3.2.5 and
3.2.6.
3.2.4 New Appendix M
Within three months of signing this amendment and receiving all
information necessary to calculate the formula set forth below,
Monsanto shall deliver to Paradigm a new Appendix M which shall
contain a list of Reservations. The number of Reservations on the
list shall be determined by the following formula:
N = 5000 - C
--------
(R X F)
where: N is the number of Reservations on the list;
C is the number of sense constructs that have been
created on the date the calculation is made
R is the success rate of Monsanto in converting
Reservations on the list into Nominations, which the parties
agree shall be [____]* for the term of this Agreement; and
F is equal to the success rate of Paradigm in converting
Nominations into sense constructs at the date the
calculation is made. F is a fraction in which the
numerator is the number of successful sense constructs
produced by Paradigm from Nominations according the
Project Plan over the two quarters preceding the
calculation and the denominator is the sum of the number
of successful sense constructs produced by Paradigm plus
the number of failures resulting from Paradigm's
attempts during the same two quarters preceding the
calculation. For purposes of this calculation, a failure
means that Paradigm has been unsuccessful in producing a
sense construct in four attempts as described in the
Project Plan.
11
Unless as otherwise agreed by Paradigm or as provided by this
Article, all future items of Monsanto DNA Information shall be
selected from Reservations on Appendix M. If Monsanto proposes to
remove a Reservation and substitute a different Reservation that is
not on the list and represents an "available gene," such agreement
by Paradigm will not be unreasonably withheld. For purposes of this
Article, an "available gene" is one which, at the time of the
proposed substitution, Paradigm has not previously analyzed for a
third party and has not previously analyzed for itself, provided
that Paradigm may only refuse a substitution on the basis that it
has previously analyzed a gene for itself for one hundred (100) such
genes during the term of the Agreement. Paradigm may not withhold
agreement for any available gene unless such gene is one (a) for
which Paradigm has created a plant transformation vector for a third
party, or (b) for which Paradigm has a written research plan with a
third party pursuant to which Paradigm intends to create a plant
transformation vector (as demonstrated by written records) and in
fact does so within six (6) months, or (c) which is the subject of
an agreement with a third party, (d) which is the subject of an
active negotiation with a third party as demonstrated by written
records that becomes subject of an agreement within twelve months of
the proposed date of substitution or (e) which is the subject of a
published patent application of Paradigm for which Paradigm has
developed functional information.
Upon receipt of each quarterly data package from Paradigm pursuant
to the Project Plan, and the necessary information for the
calculation of "N" above, Monsanto will furnish to Paradigm a list
of Reservations to be deleted from Appendix M so that the total
remaining number is determined by the above formula. If Monsanto
does not provide such list within 30 days of receipt of the
necessary information, Paradigm shall notify Monsanto of such
failure. If after an additional 15 days Monsanto has not provided
such a list, Paradigm shall have the right to select Reservations to
be deleted from the list and shall provide such selection to
Monsanto.
As an example of the operation of this process if the calculation is
performed as of the end of [___]* and the total number of successful
sense constructs produced
12
in [_________]* was [____]* and the number of failures was [___]*
during [_________]* and the total number of sense constructs created
is [____]*
F would be [____]*;
C would be [____]*;
and N would be [____]*.
3.2.5 Monsanto DNA Information Previously Analyzed.
Within ninety (90) days after submission of Appendix M, Paradigm
agrees, to the extent it has the right to do so, to make the data
from analysis it has already completed for any Reservation listed on
Appendix M available to Monsanto, and if such data meets the
requirements of a data package as described in the Project Plan,
shall be counted in the throughput targets for the Project Plan in
that quarter and if the data does not meet the requirements of a
data package, then it shall be counted in the throughput targets for
the Project Plan in the quarter that it is completed.
3.2.6 Nominations
(b) Monsanto shall submit Nominations as set forth in the Project
Plan. Paradigm shall periodically provide Monsanto with a list
of Nominations for which Paradigm has not yet commenced the
first attempt to clone a sense construct in accordance with
the Project Plan and Monsanto shall have the right to withdraw
any Nomination on such list and substitute a different
Nomination from the list of Reservations by written notice
given within five (5) business days of receipt of the list.
The withdrawn Nomination shall revert to the status of a
Reservation, subject to substitution pursuant to Section 3.2.4
at Monsanto's option.
(c) The parties shall, on a quarterly basis, review Paradigm's
success rate in converting Nominations into sense constructs
and, if appropriate to reflect such success rate, shall modify
the rate at which Nominations are provided by Monsanto
pursuant to the Project Plan.
13
7. OTHER AMENDMENTS
7.1. The Agreement is amended by deleting Section 3.5.1 from the
Agreement.
7.2. The Agreement is amended by deleting Section 4.1.1.1 from the
Agreement.
7.3. The Agreement is amended by replacing Article 11.2 with the
following:
11.2 Assignability:
The rights and obligations acquired herein by the parties are not
assignable, transferable or otherwise conveyable, in whole or in
part (by operation of law or otherwise) to any third party without
the consent of the other party, which shall not be unreasonably
withheld, except that either party may, without such consent, assign
its rights and obligations to any purchaser of all or substantially
all of the assets of the party related to this Agreement or to any
successor corporation resulting from any merger or consolidation of
a party (in either case, an "Acquirer"); provided, however, that if
the party so assigning its rights and obligations is Paradigm and
the Acquirer is not a Permitted Assignee, then (a) Paradigm may give
written notice of the proposed transaction to Monsanto at least
twenty (20) days prior to the expected closing thereof, (b) Monsanto
shall advise Paradigm in writing as to whether it will or will not
exercise its right to terminate the license granted by Section 2.12
in accordance with clause(c) of this sentence within ten (10) days
of receipt of such notice from Paradigm, and (c) if Paradigm has not
given notice in accordance with clause (a) or Monsanto has given
notice that it will exercise its right to terminate in accordance
with clause (b), Monsanto shall have the right, exercisable within
thirty (30) days after the closing or notice of the closing of such
transaction, whichever occurs later, to terminate the license
granted by Section 2.12 with respect to Monsanto Enabling Assets
except for any plant product that has been commercialized or
Submitted for Regulatory Approval at the time of the closing of such
transaction. Any Acquirer of Paradigm for which Monsanto does not,
either in whole or in part, terminate the license to Monsanto
Enabling Assets must agree in writing to
14
accept such license under the terms set out in this Agreement or
such license is terminated.
7.4 Except as expressly set forth herein, the Agreement shall remain in
full force and effect and shall not be deemed modified hereby.
15
IN WITNESS WHEREOF, the parties hereto have caused this Amendment Number 2
to be executed and delivered as of the date set forth above.
PARADIGM GENETICS, INC. MONSANTO COMPANY
By By
---------------------------------- ---------------------------------
Date Date
-------------------------------- -------------------------------
00
Xxxxxxxx X - Project Plan
Project Overview
Paradigm Genetics and Monsanto are entering into a strategic relationship to
leverage Monsanto's investment in genomics by accessing Paradigm's functional
genomics expertise and capacity. The objective of the relationship is to develop
a robust gene discovery platform, utilizing the strengths of both parties.
Monsanto will provide Paradigm with genes for analysis in Arabidopsis. These
genes will be tested as [____]* different constructs, reflecting a combination
of sense and antisense constructs (Table 1). Paradigm will use diligent effort
to provide a full data package that provides functional data to strengthen or
obtain intellectual property claims for each gene. Paradigm will provide
Monsanto with customized data packages concerning those genes including the data
from the experiments conducted in this project.
Elements of the Project Plan are subject to change based on mutual agreement
within the Project Committee, as set forth in the Agreement to which this
Project Plan is attached.
Scope
The goal of this project is the functional analysis of [____]* constructs (Table
1), over a period of six years, to determine their function and to evaluate
their potential as transgenes for improvement of agronomic and/or quality
traits. Morphological, biochemical, and stress screens for transgenic plants
carrying sense and/or antisense constructs will be collected over the entire
plant development cycle. The outlined data collection package will be applied to
Arabidopsis control and transgenic plants completing a whole life cycle. For
transgenic plants exhibiting lethal phenotypes at early developmental stages,
data will be collected up to the point of plant death and such data will be
delivered as full data sets corresponding to the respective gene.
Research Plan
Arabidopsis Transgenic Plant Generation:
Genes will be provided by Monsanto, either as sequence-verified constructs in
the appropriate binary vector or as sequence information and suggested 5' and 3'
primers for PCR-based cloning at Paradigm. All of the genes will be isolated and
cloned into at least one sense or ectopic expression system and subsequently
transformed into Arabidopsis. For all non-Arabidopsis genes, Monsanto will
supply sequence-verified sense constructs. The numbers of Plants Transformed,
Phenotypic Analyses, and Full Analyses under Appendix C assume investigation of
a pool of genes of the following composition:
Table 1.
--------------------------------------------------------------------------------
Gene Class Sense Constructs Anti-sense Constructs
--------------------------------------------------------------------------------
Arabidopsis [____]* [__________________________
___________________________
_______________]*
--------------------------------------------------------------------------------
Non-Arabidopsis [____]* minus the number of 0
anti-sense constructs in the
pipeline by 6/21/01
--------------------------------------------------------------------------------
There will be a maximum of [____]* Arabidopsis sense constructs except that the
Arabidopsis may be decreased
17
with a corresponding increase in non-Arabidopsis genes. This may represent
analysis of more than a total of [____]* Arabidopsis genes if there are
antisense constructs for which the corresponding sense construct cannot be
obtained.
Table 2 outlines what materials need to be exchanged to facilitate generation
and analysis of transgenes.
Table 2.
-------------------------------------------------------------------------------------------------------------
Monsanto has Monsanto delivers Paradigm delivers
-------------------------------------------------------------------------------------------------------------
Arabidopsis Full length, - PCR Primers - [_______________________________
partial or no - cDNA clones, if ________________________________
cDNA clone available ________________________________
- Annotated Sequence ________________________________
Information ________________________________
- Genomic DNA sequence ________________________________
- Expected PCR ________________________________
product size ________________________________
- Priority assignment ________________________________
________________________________
___________________]*
-------------------------------------------------------------------------------------------------------------
Non-Arabidopsis Full-length clone -
- -Annotated Sequence - [_______________________________
Information ________________________________
- Sequence-verified ________________________________
sense construct in ________________________________
binary vector as ________________________________
purified DNA _____________________]*
- Consensus sequence
for each construct
-------------------------------------------------------------------------------------------------------------
- -
-------------------------------------------------------------------------------------------------------------
Genes will be selected on a quarterly basis. To date, [____]* Arabidopsis genes,
including [___]* controls and [___]* non-Arabidopsis sense clones, have been
submitted. A delivery schedule to accommodate the conversion to a sense pipeline
was discussed at a meeting at Paradigm on June 18, 2001 and is shown below:
Table 3
-------------------------------------------------------------------------------------------------------------
Process Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14
-------------------------------------------------------------------------------------------------------------
Nominations Received/Quarter [_]* [__]* [_]* [__]* [_]* [_]* [_]* [_]*
-------------------------------------------------------------------------------------------------------------
Constructs/Quarter from Monsanto [_]* [__]* [_]* [__]* [_]* [_]* [_]* [_]*
-------------------------------------------------------------------------------------------------------------
* [ ]* of the [ ]* nominations for Q8 will be delivered to Paradigm by the end
of September 2001.
All Arabidopsis genes submitted from June 21, 2001 onward will be analyzed only
in the sense orientation. The intent of the plan shown above is to provide
enough nominations and clones to allow the potential of [___]* % achievement of
milestone production targets. This plan results in submission of Arabidopsis
genes and clones sufficient for the entire collaboration by the beginning of Q14
of the collaboration. For all non-Arabidopsis genes, Monsanto will provide DNA
sequence information as well as DNA constructs containing full-length open
reading frames of the respective genes suitable for expression in Arabidopsis
using vectors provided by Paradigm as described above unless otherwise
unanimously approved by the Project Committee.
All genes will be cloned using standard PCR protocols for amplification, based
on the information provided by
18
Monsanto. Paradigm will clone the Arabidopsis genes (sense and antisense) and
Monsanto will clone the non-Arabidopsis genes. Paradigm will attempt to clone
the full-length ORF (methionine to stop codon) via RT-PCR, PCR from cloned cDNA
or genomic PCR with the primer sequences supplied by Monsanto. A total of four
attempts will be made at Paradigm. The first attempt will be RT-PCR or PCR
amplification of cloned cDNA. All failures from this reaction will be subjected
to genomic PCR. Failure from this round will trigger a reordering of the cloning
primers from a different vendor; using the new primers, a second round of
attempts from both cDNA and genomic DNA will be conducted. In the case where no
construct is obtained after these four attempts, Monsanto will attempt to
perform PCR using alternative strategies and, if successful, will return the
sequence-verified clones in binary vectors to the Paradigm cloning pipeline. In
order for genes to enter Monsanto's remediation process, Paradigm will provide
CGPG numbers of declared failures via the tracking database, report the reason
for the failure, and send primers to the appropriate Monsanto cloning group. For
remediations that are returned to Monsanto by August 31, 2001, Monsanto will
have until December 31, 2001 to perform remediation and return the clones to
Paradigm. For remediations that are returned to Monsanto after August 312001,
Monsanto will have four months to perform the remediations and to return the
clones to Paradigm. If Monsanto cannot provide the clone, then Paradigm's
efforts will be counted as [___]* % of a data package for that quarter. Paradigm
must report the remediations and return the primers to Monsanto for the
remediations to ultimately count as [___]* % of a data package under the
situation where Monsanto cannot remediate. If Monsanto provides the clone,
then Paradigm will be compensated for the data package upon completion of the
analysis as if the construct had never failed and entered remediation. The
clones abandoned by Monsanto will be reported to Paradigm quarterly. A credit of
data packages, computed as [___]* % of the number of constructs for which
Monsanto failed to obtain a clone, will be counted toward Paradigm's quarterly
deliverable quota. For each quarter, this number will be credited to all
components (i.e., Constructs, Plant Transformation, Plate Phenomics, Soil
Phenomics, Full Analysis) of the quarterly quota, as presented in "Appendix C:
Project Plan Production Target Levels," and to the total project quota of
[____]* data packages.
All constructs made at Paradigm or Monsanto will be verified by DNA sequencing.
For antisense constructs, this will comprise single pass 5' and 3' sequence
runs, which will be compared with the authentic deduced protein sequence
provided by Monsanto. All sense constructs will be fully sequenced to generate a
high-quality consensus sequence. Both the nucleotide and derived amino acid
sequence corresponding to this consensus will be compared to the sequence
provided by Monsanto.
[_______________________________________________________________________________
___________________________________]* Paradigm will post all sequences obtained
from both antisense and sense constructs on the secure website for independent
confirmation of successful construct generation by Monsanto.
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
19
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*
Standard Plant Phenomics:
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*
Table 3A. Growth Stage Defining Measurements
--------------------------------------------------------------------------------
Description Measurement
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]* [_______________________________________]*
--------------------------------------------------------------------------------
20
Table 3B. Detailed Measurements
--------------------------------------------
[____________________________]*
--------------------------------------------------------------------------------
[____________________________]* [____________________________]*
--------------------------------------------------------------------------------
[____________________________]* [____________________________]*
--------------------------------------------------------------------------------
[____________________________]* [____________________________]*
--------------------------------------------------------------------------------
[____________________________]* [____________________________]*
--------------------------------------------------------------------------------
[___________]* [____________________________]*
--------------------------------------------------------------------------------
[___________]* [____________________________]*
--------------------------------------------------------------------------------
[___________]* [____________________________]*
--------------------------------------------------------------------------------
[___________]* [____________________________]*
--------------------------------------------------------------------------------
[____________________________]* [____________________________]*
--------------------------------------------------------------------------------
[___________]* [____________________________]*
--------------------------------------------------------------------------------
[______]* [____________________________]*
--------------------------------------------------------------------------------
[_______________]* [____________________________]*
--------------------------------------------------------------------------------
[_______________]* [____________________________]*
--------------------------------------------------------------------------------
[_______________]* [____________________________]*
--------------------------------------------------------------------------------
[_______________]* [______________]*
--------------------------------------------------------------------------------
[_______________]* [______________]*
--------------------------------------------------------------------------------
[_______________]* [______________]*
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*
Table 4. Dynamically scheduled data collection activities.
--------------------------------------------------------------------------------
Measurement Start Trigger Event Stop Trigger Event Plants to
Analyze(1)
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
[___________________]* [_________]* [_____________]* [_____]*
--------------------------------------------------------------------------------
21
Table 5. Growth-stage-specific data collection events.
---------------------------------------------------------------------------------------------------------------
Trigger Measurement Data
Stage(1) Type(2) 8. 9. Notes 10. Plants to
/File Analyze(4)
Code(3)
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
22
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_]* [_______]*
---------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]* [_________________________]* [___]* [______]* [_______]*
---------------------------------------------------------------------------------------------------------------
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
Biochemical Profiling:
23
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
[___________________________]*
[___________________________]*
[___________________________]*
[___________________________]*
[___________________________]*
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
Sample Processing and Extraction
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
Metabolic Profiles
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
_____________________________________________________________________________]*[
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
Table 7.
24
------------------------------------------------------------------------------
Metabolite Pathway Class
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
[_______________]* [______]* [_______________]*
------------------------------------------------------------------------------
TABLE 8
----------------------------------------------------------------------
Metabolite Pathway Class
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
25
----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
26
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
27
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
28
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
[_____________________]* [______]* [______]*
----------------------------------------------------------------------
Physiological stress screens:
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
29
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
The current list of screens along with a summary of the approved or proposed
(for PEG) SOP is listed in Table 9. .
Table 9. Summary of Physiological Stress Screens
-------------------------------------------------------------------------------------------------------------
Screen Growth Conditions Plate/Soil Attributes Quarter
Implemented
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
____________________ ________________________ ______________________
_____________]* ______]* ______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
30
-------------------------------------------------------------------------------------------------------------
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[______]* [___________________ [_______________________ [_____________________ [___]*
____________________ ________________________ ______________________
_____________]* ______]* ______________________
______________________
______________________
______________________
______________________
______]*
-------------------------------------------------------------------------------------------------------------
[_______________________________________________________________________________
______________________________________________________________________________]*
It is currently anticipated that additional screens will be developed from those
listed below and that the scope of work will be similar to the plate screens
described in the Table 9.
[______________]*
[______________]*
[______________]*
[______________]*
[______________]*
The Project Committee has the right to substitute one screen for another as long
as resources are equivalent. Specific protocols and changes to approved SOPs
will be discussed and approved by the Project Committee.
Data Format and Transfer:
Data will be collected and transferred to Monsanto in the form of computer
files.
[_______________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
31
Appendix C:
Project Plan Production Target Levels.
Production Target Levels per Quarter
Plant Plate Soil
Constructs Transformation Phenomics Phenomics Full Analysis
Q1 [_]*
Q2 [_]*
Q3 [_]* [_]*
Q4 [_]* [_]*
Q5 [_]* [_]* [_]* [_]* [_]*
Q6 [_]* [_]* [_]* [_]* [_]*
Q7 [_]* [_]* [_]* [_]* [_]*
Q8 [_]* [_]* [_]* [_]* [_]*
Q9 [_]* [_]* [_]* [_]* [_]*
Q10 [_]* [_]* [_]* [_]* [_]*
Q11 [_]* [_]* [_]* [_]* [_]*
Q12 [_]* [_]* [_]* [_]* [_]*
Q13 [_]* [_]* [_]* [_]* [_]*
Q14 [_]* [_]* [_]* [_]* [_]*
Q15 [_]* [_]* [_]* [_]* [_]*
Q16 [_]* [_]* [_]* [_]* [_]*
Q17 [_]* [_]* [_]* [_]* [_]*
Q18 [_]* [_]* [_]* [_]* [_]*
Q19 [_]* [_]* [_]* [_]* [_]*
Q20 [_]* [_]* [_]* [_]* [_]*
Q21 [_]* [_]* [_]* [_]* [_]*
Q22 [_]* [_]* [_]* [_]*
Q23 [_]* [_]* [_]*
Q24 [_]* [_]* [_]*
TOTAL [___]* [ ]* [___]* [___]* [___]*
Full analysis consists of [________________________________________________]*.
Data delivery is only relevant for those stress screens implemented in a given
quarter.
32
Appendix F
Rice Option
--------------------------------------------------------------------
Quarterly Production Target
Payments Level Payments
--------------------------------------------------------------------
Year 1
Up front access fees [________]*
Q1 [________]* [________]*
Q2 [________]* [________]*
Q3 [________]* [________]*
Q4 [________]* [________]*
Year 2
Q5 [________]* [________]*
Q6 [________]* [________]*
Q7 [________]* [________]*
Q8 [________]* [________]*
Year 3
Q9 [________]* [________]*
Q10 [________]* [________]*
Q11 [________]* [________]*
Q12 [________]* [________]*
Year 4
Q13 [________]* [________]*
Q14 [________]* [________]*
Q15 [________]* [________]*
Q16 [________]* [________]*
Year 5
Q17 [________]* [________]*
Q18 [________]* [________]*
Q19 [________]* [________]*
Q20 [________]* [________]*
--------------------------------------------------------------------
TOTAL [________]* [________]*
====================================================================
33
Appendix H
5 Year Increase in Arabidopsis
Option
--------------------------------------------------------------------
Quarterly Production Target
Payments Level Payments
--------------------------------------------------------------------
Year 1
Up-front access fees [________]*
Q1 [________]* [________]*
Q2 [________]* [________]*
Q3 [________]* [________]*
Q4 [________]* [________]*
Year 2
Q5 [________]* [________]*
Q6 [________]* [________]*
Q7 [________]* [________]*
Q8 [________]* [________]*
Year 3
Q9 [________]* [________]*
Q10 [________]* [________]*
Q11 [________]* [________]*
Q12 [________]* [________]*
Year 4
Q13 [________]* [________]*
Q14 [________]* [________]*
Q15 [________]* [________]*
Q16 [________]* [________]*
Year 5
Q17 [________]* [________]*
Q18 [________]* [________]*
Q19 [________]* [________]*
Q20 [________]* [________]*
--------------------------------------------------------------------
TOTAL [________]* [________]*
====================================================================
34
Appendix L
Monsanto Enabling Assets
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*
[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
35
________________________________________________________________________________
______________________________________________________________________________]*
36
APPENDIX M
Reservation List
37